Loading...
OTCM
RGEDF
Oct 21, Last price  
39.43
1D
-1.01%
1Q
6.59%
Name

Richter Gedeon Vegyeszeti Gyar Nyrt

Chart & performance

D1W1MN
OTCM:RGEDF chart
P/E
—
P/S
—
EPS
1,157.52
Vol. 1Y
133.27%
Shs. 5Y
-0.34%
Rev. 5Y
8.76%
Div Yld LY
3.66%
Div Yld TTM
5.46%
Revenues
862.58b
+0.59%
208,620,000,000224,076,000,000236,518,000,000267,344,000,000275,312,000,000307,868,000,000326,702,000,000351,886,000,000353,709,000,000365,220,000,000389,690,000,000444,356,000,000445,484,000,000507,794,000,000566,776,000,000630,595,000,000802,755,000,000805,158,000,000857,545,000,000862,577,987,000
Net income
215.73b
-9.83%
51,278,000,00033,336,000,00041,410,000,00050,986,000,00064,479,000,00049,281,000,00049,240,000,00042,766,000,00024,950,000,00053,863,000,00066,200,000,0008,885,000,00035,348,000,00047,135,000,000104,683,000,000139,626,000,000169,076,000,000158,850,000,000239,244,000,000215,732,244,000
CFO
271.44b
-2.84%
58,075,000,00049,868,000,00045,647,000,00078,166,000,00078,910,000,00086,447,000,00066,794,000,00073,942,000,00062,201,000,00097,689,000,00077,419,000,00083,747,000,000102,608,000,00099,129,000,000134,437,000,000139,904,000,000185,996,000,000123,670,000,000279,369,000,000271,439,976,000
Dividend
Jun 04, 20262.1534 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. The firm focuses on central nervous system, women's healthcare, cardiovascular, and OTC products. It operates through the following segments: Neuropsychiatry (CNS), General Medicines (GM), Women’s Healthcare (WHC), Biotechnology (BIO), and Pharma Other. The CNS segment focuses on building a pipeline of small molecule drug candidates mainly in the field of neuropsychiatry. The GM segment includes a traditional and generic portfolio in various therapeutic areas in the Central and Eastern European regions. The WHC segment provides pharmaceutical products for European women. The BIO segment is involved in its biotechnology platform to develop and manufacture biosimilar drugs for global markets. The Pharma Other segment relates to the remaining wholesale and retail business of the Group and all other activities. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.

Key people

Gyorgy Bagdy
Member of the Board of Directors · since 2019
Ilona Hardy
Non-Executive Independent Member of the Board of Directors
Anett Pandurics
Non-Executive Independent Member of the Board of Directors
Balint Szecsenyi
Non-Executive Independent Member of the Board of Directors · since 2018
Jonathan Robert Bedros
Independent Member of the Supervisory Board · since 2012
Independent Member of the Supervisory Board · since 2018
IPO date
Nov 09, 1994
Employees
12,167
Domiciled in
HU
Incorporated in
HU
Headquarters & legal address
GYOMROI UT 19-21
BUDAPEST, BU 1103
HU
Trading name
RICHTER GEDEON NYRT.
Previous name
RICHTER GEDEON VEGYÉSZETI GYÁR RT.

Valuation

Title
HUF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT